Lyndra Therapeutics, a clinical-stage biopharmaceutical company, has entered a strategic collaboration with Thermo Fisher Scientific Inc., through which Thermo Fisher will provide global clinical research and commercial manufacturing services to Lyndra for its long-acting oral therapies. Lyndra’s long-acting oral therapies, including lead investigational product oral weekly risperidone (LYN-005), are designed to deliver medication for a week or longer with a single oral dose. LYN-005 met its ...